IP and Patents

https://soils.wisc.edu/wp-content/cache/students/proofreading-words-per-hour.html Stemedica International has an exclusive worldwide license for Stemedica Cell Technologies’ products for neurodegenerative diseases. As part of the license, Stemedica International also has full rights to any pre-clinical and clinical protocols and results of any pre-clinical and clinical trials associated with degenerative diseases.

http://www.thegamesshed.com/2881-should-college-athletes-be-paid-essay/

Patents Issued

  • Culturing ectodermal cells under reduced oxygen tension in the presence of serum and a growth factor (U.S. Patent #8420394 B2)
  • Cellular Scaffold (U.S. Patent #8709081)
  • Cellular Scaffold – includes stem cell factors (U.S. Patent #8105380)
  • Compositions of Stem Cells and Stem Cell Factors and Methods for Their Use and Manufacture (U.S. Patent #8790638)

Patent Applications Filed With the United States Patent and Trademark Office

  • Mesenchymal Stem Cell Mediated Delivery of Therapeutic Agents
  • Angiogenically Induced Transplants and Methods for Their Use and Manufacture
  • Chimeric Transplant
  • Transgenic Therapeutic Stem Cells and Methods for their Use and Manufacture

Intellectual Property

go to link Stemedica International’s other IP assets relate to the following processes:

follow link
  • Preserving Stem Cell Differentiation Potential During Scale-Up
  • Expansion/Scale-Up of Stem Cells
  • Treatment Protocols
  • Post-Treatment Patient Protocols
  • Cell Dosages and Number of Treatments Required for Therapeutic Effect